Evan Weber
@EvanWeberPhD
Followers
3K
Following
9K
Media
73
Statuses
2K
Assistant Professor @PennMedicine @ChildrensPhila | CAR T, cancer immunotherapy, T cell fitness | https://t.co/aRpyzfCH0r
Philadelphia, PA
Joined June 2018
In our new review @trendscancer, we summarize all things CAR T cell persistence, including clinical data, multi-omics on patient CAR T, advances in CAR T engineering, and more! Amazing effort led by @kpmueller1 and @JGrenierMDPhD! Tweetorial 👇🏻 Link:
Durable CAR T persistence is among the great unsolved challenges within our field. But what do we actually mean when we say a CAR T cell is "persistent"? @JGrenierMDPhD, @EvanWeberPhD and I attempt to answer this question in our new review @trendscancer. 1/
4
11
57
This is simple: 1. Increase the budgets for NSF/NIH. 2. Stop meddling with funding for academic institutions. 3. Stop putting up barriers to recruit global talent. 4. Honor scientific peer review and 5. Remove political influences on funding decisions.
5
12
82
Two complementary studies from our group out today: a therapeutic peptide vaccine trial for fibrolamellar carcinoma (FLC) & TIRTL-Seq, our robust method for deep quantitative paired TCR sequencing a🧵w/ @MarkYarchoan & @pogorely
https://t.co/BN0pZK1JT0 &
nature.com
Nature Methods - TIRTL-seq is a high-throughput method for paired T cell receptor sequencing at the cohort scale.
2
13
38
Check out our paper out today in Immunity! Paper link: https://t.co/cno9YnaZ84 This work is the result of my PhD project in Dr. Carl June’s lab, and I’m incredibly proud to finally see it published.
cell.com
Castelli et al. show that incorporating interleukin-9 (IL-9) signaling reprograms chimeric antigen receptor (CAR) T cells to expand, persist, and resist dysfunction in solid tumors. This strategy...
2
2
7
What if nature already has the optimal cytokine solution for T cell therapy, but we just haven’t found it yet? Check out our paper out today in Immunity on IL-9 as a naturally orthogonal cytokine ideally tuned for T cell therapy https://t.co/44chA4n6rm 1/9
5
15
33
Engineering T cells (CAR T) for treatment of solid cancers has had mixed success to date. Two reports today raise the promise of using interleukin-9 as a way to raise efficacy @ImmunityCP
https://t.co/brwOZIgZOU
https://t.co/QfMQRIYWo6
7
110
389
After leukemia treatments failed, Alyssa Tapley, at age 13, was told she would die. Then, doctors tried an experimental gene-edited therapy. She became the first human to try the treatment made possible by U.S. federal funding. Now 16, she’s cancer-free and planning her future.
2
0
8
Excited to head to #SITC2025 this morning! Looking forward to great science, reconnecting with friends, and meeting new people who share a passion for cancer immunotherapy research. Stop and say hi if you see me!
1
0
18
Join experts in the IO field at Spring Scientific. Held March 25–27 in Tucson, AZ or virtual. This program will include in-depth discussions of cutting-edge technologies, and the newest clinical studies. Learn more and register here: https://t.co/9nKsiqHKVq
0
3
8
Engineering T cells with a membrane-tethered version of SLP-76 overcomes antigen-low resistance to CAR T cell therapy @NatureCancer @Majzner_Lab @mcrotiroti @DanaFarber 🇺🇸 https://t.co/hvnzK34GuD
3
16
65
🚨Our new paper is out today in Nature! We show that SARS-CoV-2 mRNA vaccines can sensitize tumors to immune checkpoint blockade (ICI) — revealing that clinically available RNA vaccines may act as potent immune modulators.
nature.com
Nature - mRNA vaccines targeting SARS-CoV-2 also sensitize tumours to immune checkpoint inhibitors.
28
70
216
Is gamma-delta CAR T the next wave? Congrats Fraietta Lab and @JoeFraietta!
Happy to announce publication of our new paper: CCR5-targeted allogeneic gamma–delta CD19 chimeric antigen receptor T cells for HIV-associated B cell-malignancy immunotherapy | Nature Biomedical Engineering Congratulations, Angel and Team!!!
1
8
44
Our new, comprehensive review on CAR T cell persistence is officially published in @CellCellPress @trendscancer. Fantastic work from lead authors @kpmueller1 @JGrenierMDPhD. Link to the full article: https://t.co/4a0lsoqHtm
2
34
127
Wow! @carlhjune @WeissmanLab & colleagues wrote an extensive and timely review on the subject of In vivo chimeric antigen receptor (CAR)-T cell therapy Published in @NatRevDrugDisc
https://t.co/yfrdQcK3Mg
Everyone - from the federal government (ARPA-H) to big pharma - is into a wave of funding/acquiring in vivo cell therapy. This article was published before the BMS-Orbital news this morning. https://t.co/tETH4S3Yci
0
33
132
Happy to share my lab’s work out today in @Cancer_Cell demonstrating that multiple myeloma relapses after CAR T therapy frequently express low BCMA levels. We develop novel SEMA4A-directed CAR T cells eradicating MM, especially under BCMA low conditions. https://t.co/cgGMkh7GIy
15
13
73
Our new @Nature study reveals a proteotoxic shock as a key mechanism of T-cell exhaustion. TexPSR (proteotoxic stress response in T-cell exhaustion) is driven by increased protein synthesis + buildup of misfolded proteins, leading to T-cell dysfunction. 👉 https://t.co/154ORc2MnD
16
40
186
Super excited to share our latest work with @MarcelaMaus , out this week in @Nature. We show that in vivo CRISPR screens can identify genes that enhance the efficacy of CAR T cell therapy. Brief explainer below! @MGBResearchNews @broadinstitute
https://t.co/rUM3TAjkPu
6
15
91
Finally, we propose a unifying framework to define the concept of CAR T "persistence". We argue that the underlying mechanisms likely differ between active tumor killing vs. long-term immunosurveillance; we refer to this as "type I" and "type II" persistence, respectively. 5/
1
3
8
Durable CAR T persistence is among the great unsolved challenges within our field. But what do we actually mean when we say a CAR T cell is "persistent"? @JGrenierMDPhD, @EvanWeberPhD and I attempt to answer this question in our new review @trendscancer. 1/
2
27
96